IN THE PRESS
Yale Startup IsoPlexis Raises $1.25M to Advance their Cell Decoding Micro-device
At IsoPlexis, we are helping researchers and clinicians discover how patients' immune systems respond to disease, at the molecular level. As therapies and illnesses have evolved, so has the need to measure and monitor patients' precise immune function. That's where we come in.
Big data meets cellular specificity for the first time. In-depth T-cell analysis requires both. This is how our technology helps determine if effective therapy responses have occurred and what they look like.
We help researchers and clinicians apply our novel technologies to their toughest problems. We then work with them to translate the large amount of patient data, from the smallest of samples, into actionable patient solutions.
IsoPlexis employs advanced single-cell analytics originally spun out of Yale University and developed in concert with leading cancer and engineering centers. See below for publication details.